86 related articles for article (PubMed ID: 2457284)
1. Does prostacyclin analogue Iloprost change blood rheology? Results from a double blind trial with intravenous application in diabetics.
Ernst E; Marshall M; Matrai A
Vasa; 1988; 17(2):89-91. PubMed ID: 2457284
[No Abstract] [Full Text] [Related]
2. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
Oberender H; Krais T; Schäfer M; Belcher G
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610
[No Abstract] [Full Text] [Related]
3. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B
Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358
[TBL] [Abstract][Full Text] [Related]
4. [Effect of benfurodil hemiscucinate (Eucilat) on various hemorheologic parameters in patients with chronic peripheral obstructive arteriopathies].
Mozzi E; Annoni F; Chiurazzi D; Rossi R; Pacini F; Martini A
Minerva Cardioangiol; 1984 Mar; 32(3):141-9. PubMed ID: 6374499
[No Abstract] [Full Text] [Related]
5. [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study].
Diehm C; Abri O; Baitsch G; Bechara G; Beck K; Breddin HK; Brock FE; Clevert HD; Corovic D; Marshall M
Dtsch Med Wochenschr; 1989 May; 114(20):783-8. PubMed ID: 2470569
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease.
Ylitalo P; Kaukinen S; Reinikainen P; Salenius JP; Vapaatalo H
Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):197-204. PubMed ID: 1694831
[TBL] [Abstract][Full Text] [Related]
7. Clinical effects of intravenous iloprost in patients with intermittent claudication.
Müller-Bühl U; Diehm C; Krais T; Zimmermann R; Mörl H; Eckstein HH
Eur J Clin Pharmacol; 1987; 33(2):127-31. PubMed ID: 2446877
[TBL] [Abstract][Full Text] [Related]
8. [Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease].
Stiegler H; Diehm C; Grom E; Martin M; Mörl H; Rudofsky G; Vogelberg KH
Vasa Suppl; 1992; 35():164-6. PubMed ID: 1481031
[No Abstract] [Full Text] [Related]
9. [Double-blind placebo-controlled study of the behavior of tcPO2 during intravenous infusion of prostaglandin E1 in patients with severe arterial occlusive disease].
Creutzig A; Caspary L; Alexander K
Vasa Suppl; 1992; 35():36-8. PubMed ID: 1481055
[No Abstract] [Full Text] [Related]
10. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial.
Belch JJ; McKay A; McArdle B; Leiberman P; Pollock JG; Lowe GD; Forbes CD; Prentice CR
Lancet; 1983 Feb; 1(8320):315-7. PubMed ID: 6130330
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
12. Prostacyclin in peripheral arterial occlusive disease (PAOD): clinical and hemodynamic findings in patients with PAOD stage III and IV.
Valentin A; Karnik R; Sehnal E; Slany J
Prog Clin Biol Res; 1987; 242():457-62. PubMed ID: 3313420
[No Abstract] [Full Text] [Related]
13. [Administration of prostaglandin E1 in diabetics and non-diabetic patients with severe Fontaine stage IIb arterial occlusive disease].
Hinderer S; Brachmann R; Nedder KH; Bucher J; Beischer W
Vasa; 1991; 20(2):100-8. PubMed ID: 1877328
[TBL] [Abstract][Full Text] [Related]
14. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost.
Balzer K; Bechara G; Bisler H; Clevert HD; Diehm C; Heisig G; Held K; Mahfoud Y; Mörl H; Rücker G
Int Angiol; 1991; 10(4):229-32. PubMed ID: 1724669
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of i.v. prostacyclin on aspirin-induced asthma.
Nizankowska E; Czerniawska-Mysik G; Szczeklik A
Eur J Respir Dis; 1986 Nov; 69(5):363-8. PubMed ID: 3539632
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental--results of a multicenter double-blind study].
Rudofsky G; Haussler KF; Künkel HP; Schneider-May H; Spengel F; Symann O; Werner HJ; Rössner M
Vasa Suppl; 1987; 20():375-8. PubMed ID: 3321494
[No Abstract] [Full Text] [Related]
17. [Blood fluidity in essential hypertension, arterial occlusive disease and diabetic angiopathies].
Sternitzky R; Hänsgen K; Podhaisky H
Z Gesamte Inn Med; 1991 Nov; 46(16):610-4. PubMed ID: 1792802
[TBL] [Abstract][Full Text] [Related]
18. [The effect of naftidrofuryl on macro- and microcirculation, tissue oxygen supply and blood rheology].
Jung F; Kiesewetter H
Vasa Suppl; 1989; 27():38. PubMed ID: 2696110
[No Abstract] [Full Text] [Related]
19. Blood rheology changes during bezafibrate treatment.
Caimi G; Francavilla G; Romano A; Catania A; Santonocito G; Sarno A
Br J Clin Pract; 1988 Nov; 42(11):456-8. PubMed ID: 3076782
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.
Darius H; Hossmann V; Schrör K
Klin Wochenschr; 1986 Jun; 64(12):545-51. PubMed ID: 2426514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
